B.N.Rathi Securities Ltd.

Company Profile

Smart Quotes

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private

BSE872.858.35 (+0.97 %)

PREV CLOSE ( ) 864.50

OPEN PRICE ( ) 868.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1940

TODAY'S LOW / HIGH ( )859.50 877.50

52 WK LOW / HIGH ( )605.2 971

NSE873.354.6 (+0.53 %)

PREV CLOSE( ) 868.75

OPEN PRICE ( ) 869.95

BID PRICE (QTY) 873.35 (10)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 102187

TODAY'S LOW / HIGH( ) 857.90 879.00

52 WK LOW / HIGH ( )605 971.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 2007

Management Info

Amit Indubhushan Bakshi - Chairman Amit Indubhushan Bakshi - Managing Director

Registered Office

Address Shivarth Ambit, Plot No. 142/2,Ramdas Road, Off S B R,Near Swati Bungalows, Bodakdev,
Ahmedabad,
Gujarat-380054

Phone 079 30451000 / 1001

Email eris@erislifesciences.com

Website www.eris.co.in

Registrars Details

Link Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

21Mar Eris Lifesciences informs about analys
Eris Lifesciences has informed that the transcript of the Analyst and In..

15Mar Eris Lifesciences acquires Biocon Biol
Eris Lifesciences has acquired Biocon Biologics’ India branded formulati..

14Mar Eris Lifesciences informs about outcom
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

20Feb Eris Lifesciences informs about transc
Eris Lifesciences has informed that the transcript of the Analyst and In..

16Feb Eris Lifesciences acquires 51% stake i
Eris Lifesciences has completed acquisition of 51% equity stake in Swiss..

Financials

in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	316.55	3980.08
Gross Profit	346.43	4369.11
Operating Profit	778.67	5223.78
Net Sales	3244.14	13307.25

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 25945.60 (0.89%)	M.Cap ( in Cr)55132.59
Astrazeneca Pharma I (BSE) 5311.15 (2.00%)	M.Cap ( in Cr)13277.88
Neuland Laboratories (BSE) 7447.45 (1.24%)	M.Cap ( in Cr)9555.00
Alkem Laboratories (BSE) 5168.50 (1.04%)	M.Cap ( in Cr)61797.17
AMI Organics (BSE) 1205.15 (3.92%)	M.Cap ( in Cr)4444.66

Shareholding Pattern

	PROMOTERS	54.9%
	NON-INSTITUTION	15.19%
	MUTUAL FUNDS/UTI	14.92%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund-Reg(IDCW)	2.94
HDFC Pharma and Healthcare Fund-Reg(G)	2.45
Bank of India Small Cap Fund-Reg(G)	1.98
Quantum Small Cap Fund-Reg(G)	1.85
HDFC Small Cap Fund-Reg(G)	1.69
Bank of India Multi Cap Fund-Reg(G)	1.60
Bank of India Mfg & Infra Fund-Reg(G)	1.55

Investor Alert

1) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. 2) For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors. 3) For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors. 4) No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. 5) Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. 6) This is to inform that we B N Rathi securities Ltd not required to have a Business Continuity/DR plan under the existing regulatory provisions.

ATTENTION INVESTORS | KYC | IPO

Prevent Unauthorised transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/DP. Receive information of your transactions directly from Exchanges/Depositories on your mobile/email at the end of the day. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account......Issued in the interest of investors. SEBI Circular - Investor Grievance Redress Mechanism - New Policy Measures. Kindly refer at Policies.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account

REGISTRATION NOS: SEBI Registration No: INZ000160834 (BSE-3233 | NSE-07141| MCX-56475) CDSL : SEBI Regn No. IN-DP-612-2021. AMFI-Registered Mutual Fund Distributor: B.N.Rathi Securities Ltd - ARN-77516: (B.N.Rathi is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.) CIN: L65993TG1985PLC005838

GRIEVANCE CONTACT Investor Grievance Contact: investorgrievances@bnrsecurities.com | DP Investor Grievance: investorgrievances@bnrsecurities.com Investor Protection and Arbitration Exchange Circulars and Rules - NSE,BSE and MCX.

In case of member having a website, member has created awareness amongst clients / investors with regard to procedure of pledge/ re-pledge of securities and displayed the guidelines on the homepage of their respective websites at a prominent place as required in Exchange circular ref no. NSE/INSP/45565 dated Sep 02,2020 Trading members had displayed the set of standard documents/policies on their own website for information.

SEBI SCORES LETTER OF AUTHORITY BROKERS NORMS RMS POLICY PMLA-POLICY SURVEILLANCE POLICY KYC MANDATORY - 6 ATTRIBUTES EVoting CDSL EVoting NSDL

DISCLAIMER INACTIVE CLIENT POLICY PRIVACY POLICY TERMS & CONDITIONS COMPANY POLICIES INVESTOR GRIEVANCE REDRESSAL POLICY INVESTOR CHARTER INVESTOR CHARTER - DP INVESTOR CHARTER - RESEARCH ANALYST INVESTOR CHARTER IGC MIS ADVISORY FOR INVESTORS BNRSL-DISCLAIMERS RESEARCH REPORTS